• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Catalent Inc (NY: CTLT )

    57.91 -0.08 (-0.14%)
    Official Closing Price Updated: 7:00 PM EDT, Jul 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 939,764
    Open 58.00
    Bid (Size) 53.51 (1)
    Ask (Size) 58.58 (1)
    Prev. Close 57.99
    Today's Range 57.84 - 58.12
    52wk Range 31.80 - 60.20
    Shares Outstanding 170,341,553
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Catalent Completes $25 Million Expansion of its Clinical Supply Facility in Schorndorf, Germany
    From Catalent, Inc.
    Via Business Wire
    Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
    Catalent shares rise after Sarepta Therapeutics' Elevidys expanded approval. Despite uncertainties, Catalent's risk/reward profile improves. 
    Via Benzinga

    Performance

    YTD
    +28.55%
    +28.55%
    1 Month
    +5.64%
    +5.64%
    3 Month
    +4.38%
    +4.38%
    6 Month
    +17.68%
    +17.68%
    1 Year
    +21.71%
    +21.71%

    More News

    Read More
    S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
    Via Investor's Business Daily
    Topics Stocks
    Exposures US Equities
    Catalent Stockholders Approve Transaction with Novo Holdings
    From Catalent, Inc.
    Via Business Wire
    Beyond The Numbers: 6 Analysts Discuss Catalent Stock
    Via Benzinga
    (CTLT) - Analyzing Catalent's Short Interest
    Via Benzinga
    Soaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now?
    Via The Motley Fool
    Hedge Funds Tweak Portfolios In Q1: Marvell, TD Synnex, AES Get More Love As Focus Shifts To AI
    Via Benzinga
    CTLT Stock Earnings: Catalent Misses EPS, Misses Revenue for Q3 2024
    Via InvestorPlace
    Catalent, Inc. Reports Third Quarter Fiscal 2024 Results
    From Catalent, Inc.
    Via Business Wire
    Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
    Via Benzinga
    Robbins LLP Reminds Stockholders it is Investigating the Acquisition of Catalent, Inc. (CTLT)
    From Robbins LLP
    Via Business Wire
    Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
    Via Benzinga
    Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings
    From Robbins LLP
    Via GlobeNewswire
    Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
    Via The Motley Fool
    Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
    Via Talk Markets
    Did Novo Nordisk Just Get a Jump on Eli Lilly?
    Via The Motley Fool
    Exposures Product Safety
    The Top 3 Pharma Stocks to Buy in March2024
    Via InvestorPlace
    Novo Nordisk Sets Timeframe For Its Next-Gen Experimental Obesity Drug
    Via Benzinga
    Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment
    From Catalent, Inc.
    Via Business Wire
    Escalating Demand for Obesity Drugs Creates Time-Sensitive Race for Eli Lilly, Novo Nordisk
    Via Benzinga
    Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why
    Via The Motley Fool
    Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla
    Via Benzinga
    Topics ETFs Stocks
    Exposures US Equities
    Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit)
    Via Benzinga
    Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.